HC Wainwright Has Bearish Forecast for ARQT Q1 Earnings

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Stock analysts at HC Wainwright lowered their Q1 2027 earnings estimates for Arcutis Biotherapeutics in a research report issued on Thursday, November 5th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of $0.07 for the quarter, down from their previous forecast of $0.08. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is $0.43 per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ Q2 2027 earnings at $0.14 EPS and Q3 2027 earnings at $0.22 EPS.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.12). The company had revenue of $143.92 million for the quarter, compared to analyst estimates of $142.59 million. Arcutis Biotherapeutics had a net margin of 5.88% and a return on equity of 14.96%.

Other analysts have also issued research reports about the company. Jefferies Financial Group reissued a “buy” rating and issued a $39.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, October 8th. Morgan Stanley raised their price target on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Wall Street Zen cut Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 10th. Cantor Fitzgerald assumed coverage on Arcutis Biotherapeutics in a report on Thursday, October 15th. They issued an “overweight” rating and a $48.00 price objective on the stock. Finally, TD Cowen increased their target price on Arcutis Biotherapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $39.75.

Arcutis Biotherapeutics Stock Performance

Shares of ARQT stock opened at $27.00 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.67 and a current ratio of 2.92. The firm has a market cap of $3.39 billion, a P/E ratio of 128.58 and a beta of 1.66. The firm’s 50 day moving average price is $27.15 and its 200-day moving average price is $25.37. Arcutis Biotherapeutics has a one year low of $19.30 and a one year high of $34.80.

Insider Activity at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, EVP Masaru Matsuda sold 40,000 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $34.32, for a total value of $1,372,800.00. Following the completion of the transaction, the executive vice president owned 111,289 shares in the company, valued at $3,819,438.48. The trade was a 26.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Howard G. Welgus sold 4,728 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $26.93, for a total value of $127,325.04. Following the sale, the director directly owned 35,207 shares in the company, valued at $948,124.51. This represents a 11.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 123,932 shares of company stock worth $3,553,077 over the last 90 days. 9.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Arcutis Biotherapeutics during the 2nd quarter worth about $276,502,000. Bank of America Corp DE acquired a new stake in Arcutis Biotherapeutics in the 2nd quarter valued at about $78,330,000. Jupiter Topco LLC purchased a new position in shares of Arcutis Biotherapeutics in the 2nd quarter valued at about $36,989,000. Bamco Inc. NY purchased a new position in shares of Arcutis Biotherapeutics in the 2nd quarter valued at about $32,857,000. Finally, Simplify Asset Management Inc. purchased a new position in shares of Arcutis Biotherapeutics in the 3rd quarter valued at about $22,885,000.

Key Stories Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis enrolled its first participant in a Phase 3 trial testing ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the treatment’s use, though any commercial benefit depends on trial results and timing. Phase 3 trial announcement
• Neutral Sentiment: The company appointed Rob Lisicki as chief commercial officer, a move that may support its commercial execution; the announcement did not specify an immediate financial impact. Chief commercial officer appointment
• Negative Sentiment: Third-quarter EPS of $0.06 missed analyst expectations of about $0.17–$0.18, despite revenue of $143.92 million topping the $142.59 million estimate. The earnings shortfall has been associated with pressure on the shares. Article on Q3 earnings reaction
• Negative Sentiment: HC Wainwright reduced its 2027 quarterly EPS forecasts: Q1 to $0.07 from $0.08, Q2 to $0.14 from $0.19, and Q3 to $0.22 from $0.25. These cuts add to concerns about the earnings outlook.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.